Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Q 122

Next Previous
Drug Profile

Q 122

Alternative Names: MSX-122; Q122

Latest Information Update: 29 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Emory University; University of Queensland
  • Developer Altiris Therapeutics; QUE Oncology
  • Class Anti-inflammatories; Antineoplastics; Pyrimidines; Small molecules
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Hot flashes

Highest Development Phases

  • Phase II Hot flashes; Vasomotor symptoms
  • Discontinued Solid tumours

Most Recent Events

  • 29 Nov 2022 Q 122 is still in phase II trials for Vasomotor symptoms and Hot Flashes in USA, Australia and New Zealand (QUE oncology website, November 2022)
  • 11 Nov 2022 Efficacy and adverse events data from a phase II trial in Vasomotor symptoms released by QUE Oncology
  • 09 Sep 2020 Que Oncology completes a phase II trial in Vasomotor symptoms in USA, Australia, New Zealand (NCT03518138)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top